Comparative Study Between Oral and Vaginal Misoprostol for Induction of Labor in Nulliparous Pregnant Women at or Beyond Completed 41 Weeks

Mahmoud Abdelhameed, Heba El Sawah, Marwa Sharaf, El Sayed Omran, Sally El Attar
{"title":"Comparative Study Between Oral and Vaginal Misoprostol for Induction of Labor in Nulliparous Pregnant Women at or Beyond Completed 41 Weeks","authors":"Mahmoud Abdelhameed, Heba El Sawah, Marwa Sharaf, El Sayed Omran, Sally El Attar","doi":"10.21608/ebwhj.2023.251942.1279","DOIUrl":null,"url":null,"abstract":"Background: Misoprostol applied vaginally has been shown to be an effective method of inducing labor; nevertheless, pregnant women may be resistant to digital examination and there is a possibility of infection. Therefore, oral misoprostol was attempted to induce labor. Objective: The aim of this study was to evaluate the safety and effectiveness of vaginal versus oral misoprostol for inducing labor in nulliparous women at or after 41 completed weeks of pregnancy. Materials and Methods: Eighty nulliparous women, divided into two groups, were eligible for labor induction at 41 weeks or more. In Group 1, 40 pregnant women got 25 μg vaginal misoprostol every six hours until a response was achieved, with a maximum of four doses. For Group 2, 40 pregnant women took oral misoprostol at a dose of 25 μg every six hours until a response was obtained, with a maximum of four doses. Results: Oral and vaginal misoprostol were comparable regarding the duration from inducing labor to onset of the active stage, interval from inducing labor to the delivery, cesarean deliveries, dosage requirements, and maternal and neonatal outcomes. However, the process of labor augmentation with oxytocin was dramatically reduced in the vaginal group. Conclusion : 25 μg oral misoprostol is as effective and safe as 25 μg vaginal misoprostol for inducing labor in nulliparous women with an unripe cervix at or beyond completed 41 weeks.","PeriodicalId":12080,"journal":{"name":"Evidence Based Women's Health Journal","volume":"823 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Evidence Based Women's Health Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21608/ebwhj.2023.251942.1279","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Misoprostol applied vaginally has been shown to be an effective method of inducing labor; nevertheless, pregnant women may be resistant to digital examination and there is a possibility of infection. Therefore, oral misoprostol was attempted to induce labor. Objective: The aim of this study was to evaluate the safety and effectiveness of vaginal versus oral misoprostol for inducing labor in nulliparous women at or after 41 completed weeks of pregnancy. Materials and Methods: Eighty nulliparous women, divided into two groups, were eligible for labor induction at 41 weeks or more. In Group 1, 40 pregnant women got 25 μg vaginal misoprostol every six hours until a response was achieved, with a maximum of four doses. For Group 2, 40 pregnant women took oral misoprostol at a dose of 25 μg every six hours until a response was obtained, with a maximum of four doses. Results: Oral and vaginal misoprostol were comparable regarding the duration from inducing labor to onset of the active stage, interval from inducing labor to the delivery, cesarean deliveries, dosage requirements, and maternal and neonatal outcomes. However, the process of labor augmentation with oxytocin was dramatically reduced in the vaginal group. Conclusion : 25 μg oral misoprostol is as effective and safe as 25 μg vaginal misoprostol for inducing labor in nulliparous women with an unripe cervix at or beyond completed 41 weeks.
口服米索前列醇与阴道米索前列醇对 41 周或超过 41 周的无阴道孕妇引产的比较研究
背景:经阴道使用米索前列醇已被证明是一种有效的引产方法;然而,孕妇可能对数字检查有抵触情绪,而且有感染的可能。因此,我们尝试使用口服米索前列醇进行引产。研究目的本研究旨在评估阴道与口服米索前列醇引产的安全性和有效性。材料和方法:80名无产科背景的孕妇被分为两组,分别在妊娠41周或41周以上进行引产。在第一组中,40 名孕妇服用 25 μg 阴道米索前列醇,每 6 小时一次,直到有反应为止,最多服用 4 次。第二组中,40 名孕妇口服米索前列醇,剂量为每六小时一次,每次 25 微克,直到有反应为止,最多服用四次。研究结果在从引产到活跃期开始的持续时间、从引产到分娩的间隔时间、剖宫产、剂量要求以及产妇和新生儿结局方面,口服和阴道用米索前列醇的效果相当。然而,阴道组使用催产素催产的过程大大减少。结论:对于宫颈尚未成熟、已满 41 周或超过 41 周的无子宫产妇,口服 25 μg 米索前列醇与阴道用 25 μg 米索前列醇引产同样有效、安全。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信